フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the...
Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”), a pharmaceutical company developing and commercializing products to improve...
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creator of COLD...
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer PR Newswire EDMONTON, June...
Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to...
Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer PR...
Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti - PSA IgE...
Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and...
Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer PR...
Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy PR Newswire EDMONTON, July 10...
Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States PR Newswire EDMONTON, June 14, 2012...
Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs PR Newswire EDMONTON, June 5...
Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology PR...
Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011) PR Newswire EDMONTON...
Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約